European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Viprinex Research AG, Uetersen, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Viprinex Research AG

Identification

Ut
District Court of Pinneberg HRB 8752 PI
EUID
DEX1321R.HRB8752PI

Address

Pinnauallee 4, 25436 Uetersen, Germany

Corporate purpose

The development of drugs from snake venom as well as the conduct of clinical studies to obtain drug approvals, the granting of licenses for the further development and/or marketing of finished drugs and the marketing of active ingredients and drugs.

History

Network

Loading network
tax haven banner

Publications

1 Sept 2025 via Nordmark Pharma GmbH also 12/09/2024, 19/09/2023, 09/06/2022, 06/07/2021
Shareholder: Nordmark Pharma GmbH
20 Aug 2025 via Nordmark Arzneimittel Holding GmbH & Co. KG also 24/10/2024, 07/08/2023, 16/08/2022, 18/11/2021
Shareholder: Nordmark Arzneimittel Holding GmbH & Co. KG
27 Jun 2025
No longer Authorized signatory (ppa): Marc Janssen
22 Jul 2024
Member of the Executive Board: Jörg Clemens · No longer Authorized signatory (ppa): Jan Peters
6 Jun 2024
Aufsichtsrat
24 Apr 2024
Original document: “Liste der Aufsichtsratsmitglieder“
14 Jun 2023
List of board members
23 May 2023
Aufsichtsrat
1 Apr 2023
Original document: “Liste der Aufsichtsratsmitglieder“
9 Jun 2022
Authorized signatory (ppa): Marc Janssen, Jan Peters
12 May 2022
Aufsichtsrat
15 Feb 2022
List of board members
9 Dec 2021
No longer Member of the Executive Board: Jan Lüdemann
7 Dec 2021
Original document: “Liste der Aufsichtsratsmitglieder“
24 Feb 2021
Control: Nordmark Pharma GmbH, Nordmark Arzneimittel Holding GmbH & Co. KG · Control: Nordmark Pharma GmbH, Nordmark Arzneimittel Holding GmbH & Co. KG …
24 Aug 2020 via Nordmark Arzneimittel Holding GmbH & Co. KG also 24/08/2020, 10/08/2020, 10/08/2020, 24/09/2019, 24/09/2019, 24/09/2019, 21/05/2019, 21/05/2019, 09/10/2018, 09/10/2018, 07/06/2018, 07/06/2018, 05/12/2017, 05/12/2017, 16/10/2017, 16/10/2017, 07/12/2016, 07/12/2016, 22/11/2016, 22/11/2016, 05/11/2015, 05/11/2015, 04/11/2015, 04/11/2015 and 16 more
Shareholder: Nordmark Arzneimittel GmbH & Co. KG
6 Aug 2020
Aufsichtsrat
20 May 2020
List of board members
1 Apr 2020
Member of the Executive Board: Jörg Clemens · No longer Member of the Executive Board: Detlev Baumeister, Jörn Tonne
22 Jan 2016
No longer Member of the Executive Board: Manfred Kurfürst
11 Jan 2016
No longer Member of the Executive Board: Manfred Kurfürst
11 Dec 2014 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
11 Dec 2014 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
14 Nov 2012
Annual report for the year ending 31/12/2011 · Balance sheet for 31/12/2011
5 Jan 2012 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
5 Jan 2012 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
6 Dec 2011
Annual report for the year ending 31/12/2010 · Balance sheet for 31/12/2010
20 May 2011
The entry relating to the article shall be corrected ex officio and shall be entered as follows: the development of medicinal products derived from snake venom, the conduct of clinical trials to …
17 May 2011 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
17 May 2011 as Viprinex Research AG, Uetersen
Word figurative mark: “Viprinex“
12 May 2011
The entry relating to the article shall be corrected ex officio and shall be entered as follows: the development of medicinal products derived from snake venom, the conduct of clinical trials to …
29 Apr 2011
By resolution of the Annual General Meeting on 12.04.2011, the Articles of Association were amended to § 9, § 15 and § …
19 Apr 2011
Legal form: By resolution of the Annual General Meeting of 12.04.2011, the articles of association were amended in § 9 …
14 Apr 2011
Original document: “Gesellschaftsvertrag / Satzung / Statut“
1 Oct 2010
Control: Nordmark Arzneimittel GmbH & Co. KG · Control: Nordmark Arzneimittel GmbH & Co. KG
9 Sept 2010
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
6 Aug 2010
Reg­is­tra­tion · CxO (4) · Address · Capital: €500,000 · Proxy policy · Company statute · The research and development of snake venom medicinal products and the conduct of clinical trials for the …
22 Jul 2010
Reg­is­tra­tion · CxO (4) · Address · Capital: €500,000 · Name: Viprinex Research AG · Proxy policy · Company statute · The research and development of snake venom medicinal products and the conduct …
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Viprinex Research AG, Uetersen, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.